FDA Acts Quickly On Lifecore’s Intergel PMA Following Dispute Resolution
This article was originally published in The Gray Sheet
Executive Summary
FDA has approved Lifecore Biomedical's Gynecare Intergel adhesion prevention solution for the indication sought by the company with the addition of several warnings and contraindications
You may also be interested in...
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
Lifecore Biomedical CEO Resigns; Intergel Withdrawal Review Continues
Dennis Allingham's replacement of former Lifecore Biomedical President & CEO James Bracke comes amid an ongoing review of reported adverse events related to the firm's Intergel adhesion barrier